

NeuroMetrix Marks 10th Year Anniversary of Listing on NASDAQ

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) reported today that it had reached the 10th anniversary of its initial listing on NASDAQ.

NeuroMetrix debuted on NASDAQ on July 22, 2004 as a medical device company with unique technology that allowed nerve conduction studies, previously the domain of specialist physicians, to be performed at the point-of-care. This led to the creation of a new market as primary care and other physicians expanded the scope of their services to include nerve testing and patients benefitted from its convenience. Reimbursement changes over the years eroded this market and NeuroMetrix shifted its focus to the diabetes sector. During the past three years, the Company has launched two important new products: NC-stat DPNCheck which is a fast, accurate, quantitative test for diabetic peripheral neuropathy, and SENSUS Pain Management which is a therapeutic device for the treatment of chronic pain including painful diabetic neuropathy. Today NeuroMetrix is widely viewed as an emerging business in the fast-growing field of wearable health electronics. SENSUS is a good example of products in this category.

"Our NASDAQ listing has been an important factor in our access to capital markets and has provided orderly trading in our stock for investors," said Shai Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. "We are very pleased with our long association with NASDAQ."

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The Company has a major focus on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at \$14 billion in the United States. The Company markets the SENSUS device for treating chronic pain, focusing on physicians managing patients with neuropathic pain such as painful diabetic neuropathy. The Company also markets DPNCheck®, which is a rapid, accurate, and quantitative point-of-care test for peripheral neuropathies such as diabetic neuropathy. This product is used to detect neuropathies at an early stage and to guide treatment. For more information, please visit <http://www.SENSUSRx.com> or <http://www.NeuroMetrix.com>.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media